Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 34Neoplasm Metastasis 3Osteoporosis 2Fractures, Bone 2Arthralgia 2Polycystic Ovary Syndrome 1Neurotoxicity Syndromes 1Neoplasms, Hormone-Dependent 1Fatigue 1Estrogen Receptor and/or Progesterone Receptor Positive 1Carcinoma, Lobular 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Ductal, Breast 1Breast Neoplasms, Male 1Breast Carcinoma In Situ 1Breast Cancer Metastatic 1Bone Diseases, Metabolic 1

Interventions

Gemcitabine 74Capecitabine 60Paclitaxel 59Fluorouracil 58Oxaliplatin 57Bevacizumab 51Docetaxel 50Leucovorin 48Nivolumab 40Cisplatin 40Irinotecan 39Carboplatin 37Cetuximab 34pembrolizumab 32Radiosurgery 32Trastuzumab 30Radiotherapy 27Everolimus 24Sorafenib 23Pemetrexed 20Doxorubicin 20Albumin-Bound Paclitaxel 20Ipilimumab 19Cyclophosphamide 19Panitumumab 18Zoledronic Acid 17Lapatinib 17Erlotinib Hydrochloride 17Prednisone 16pazopanib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Neoplasm Metastasis × Aromatase Inhibitors × Clear all
NCT06086340 2025-11-18

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

Pfizer

Completed
779 enrolled 9 charts
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02188745 2024-07-17

POLLY

Dartmouth-Hitchcock Medical Center

Phase 2 Completed
19 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT01446159 2020-06-02

Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer

MedImmune LLC

Phase 2 Completed
188 enrolled 32 charts
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡